Lorlatinib is named as a drug or biological intervention in 10 clinical trials in our China, USA, India and UK trial registers, 3 of which are recruiting. Lead sponsors include Pfizer (4), Guangdong Association of Clinical Trials (2) and Nuvectis Pharma, Inc. (1). Registered phases: Observational, Phase 1, Phase 4, Phase 2 and Phase 3. Conditions studied include ALK Positive Non-small Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung; NSCLC.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07617337 | AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer (ClinicalTrials.gov ↗) ALK Positive Non-small Cell Lung Cancer |
Phase 1 | Recruiting |
| NCT07784959 | Study of NXP900 With Lorlatinib in ALK+ Lung Cancer (ClinicalTrials.gov ↗) ALK Positive, ALK Positive Non-small Cell Lung Cancer, NSCLC |
Phase 1 | Recruiting |
| NCT06361589 | Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients (ClinicalTrials.gov ↗) ALK-positive Non-small Cell Lung Cancer, Real World Study |
Observational | Recruiting |
| NCT07750704 | Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC (ClinicalTrials.gov ↗) ALK Positive Non-small Cell Lung Cancer |
Phase 2 | Not yet open |
| NCT05144997 | Lorlatinib Continuation Study (ClinicalTrials.gov ↗) Non-Small-Cell Lung Cancer, NSCLC |
Phase 4 | Active, closed |
| NCT06282874 | Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases (ClinicalTrials.gov ↗) Carcinoma, Non-Small-Cell Lung, Brain Metastases, Leptomeningeal Metastasis |
Phase 4 | Active, closed |
| NCT03052608 | A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC (ClinicalTrials.gov ↗) Carcinoma, Non-Small-Cell Lung |
Phase 3 | Active, closed |
| NCT05740943 | Induction Lorlatinib in Stage III Non-small Cell Lung Cancer (ClinicalTrials.gov ↗) Stage III NSCLC, Surgery |
Phase 2 | Active, closed |
| NCT07556549 | A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC (ClinicalTrials.gov ↗) Non-Small Cell Lung Cancer ALK-positive |
Observational | Active, closed |
| NCT07567352 | A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment (ClinicalTrials.gov ↗) Non-Small-Cell Lung, ALK-positive Advanced NSCLC, ALK-positive Non-small-cell Lung Cancer |
Observational | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| ALK Positive Non-small Cell Lung Cancer | 3 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| NSCLC | 2 |
| ALK Positive | 1 |
| ALK+ Non-Small-Cell Lung Carcinoma | 1 |
| Non-Small-Cell Lung Cancer | 1 |
| Non-Small-Cell Lung | 1 |
| ALK-positive Advanced NSCLC | 1 |
| ALK-positive Non-small-cell Lung Cancer | 1 |
| ALK-positive NSCLC | 1 |
| Brain Metastases | 1 |
| Leptomeningeal Metastasis | 1 |
| ALK-positive Non-small Cell Lung Cancer | 1 |
| Real World Study | 1 |
| Stage III NSCLC | 1 |
| Surgery | 1 |
| Non-Small Cell Lung Cancer ALK-positive | 1 |
| Lead sponsor | Trials |
|---|---|
| Pfizer | 4 |
| Guangdong Association of Clinical Trials | 2 |
| Nuvectis Pharma, Inc. | 1 |
| Chugai Pharmaceutical | 1 |
| Sichuan Cancer Hospital and Research Institute | 1 |
| Guangdong Provincial People's Hospital | 1 |
| Register | Lorlatinib trials |
|---|---|
| Clinical trials in China | 7 |
| Clinical trials in USA | 5 |
| Clinical trials in India | 2 |
| Clinical trials in UK | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Lorlatinib works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Lorlatinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.